Feedstuffs is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Elanco announces approval of Prevacent use in sows

Scott Olson_Getty Images News hogs huddled together at hog farm
Modified-live PRRS vaccine had previously been approved in the fall of 2018 for use in pigs two weeks of age and older.

Elanco Animal Health Inc. announced that Prevacent PRRS has been licensed for use in sows and gilts against the reproductive form of porcine reproductive and respiratory syndrome (PRRS), when vaccinated six weeks prior to breeding.

Prevacent, a modified-live PRRS vaccine, had previously been approved in the fall of 2018 for use in pigs two weeks of age and older, and had shown to be effective against PRRS respiratory disease, Elanco said.

PRRS cost the U.S. swine herd industry $664 million per year from 2005 to 2010, translating into $1.8 million per day or $114.71 per sow annually, Elanco noted, adding that PRRS increases mortality and reduces growth performance, which reduces sustainability and compromises herd well-being.

With new approval for use in sows and gilts, Elanco said Prevacent PRRS control expands use across production phases.

“With limited post-vaccination growth depression and the contemporary lineage, Elanco is excited to offer the industry an expansion of the Prevacent label to include a reproductive claim. We look forward to working with veterinarians and producers as we work to improve control of PRRS,” said Dr. Mark Hammer, Elanco consulting veterinarian.

Additional pack and dose sizes of Prevacent will be available in the fall of 2020 for added flexibility and convenience across production segments, Elanco said. More information associated with Prevacent’s new sow indication can be found at ControlPRRS.com.

According to Elanco, Prevacent was found to be safe for all gestational stages as shown by vaccination reactions comparable to controls and no adverse impacts on farrowing rate. Prevacent-vaccinated gilts also demonstrated a reduction in the duration and level of viremia, or the presence of the PRRS virus in the blood, as well as improvements in piglet viability and birth weight compared to controls.

Prevacent license approval in sows expands Elanco’s Full Value portfolio of swine products to manage disease challenges, minimize variation and mitigate mortality to ultimately optimize pig health.

Elanco is a global animal health company that develops products and knowledge services to prevent and treat disease in food animals and pets in more than 90 countries.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.